Biden defends Trump-era drug pricing rule on copay accumulators – STAT
Home
News
Business
Washington
Science
Public Health
Disease
Features
Newsletters
Opinion
Columns
Podcasts
Video
Tools & Trackers
Events
Community
Don't miss out
Subscribe to STAT+ today, for the best life sciences journalism in the industry
for the latest news and insights in the world of life sciences, medicine, biotech, and pharma
at exclusive live and virtual events hosted by STAT
with subscriber-only newsletters delivered to your inbox daily
with our premium data tools
for the latest news and insights in the world of life sciences, medicine, biotech, and pharma
at exclusive live and virtual events hosted by STAT
with subscriber-only newsletters delivered to your inbox daily
with our premium data tools
for the latest news and insights in the world of life sciences, medicine, biotech, and pharma
at exclusive live and virtual events hosted by STAT
with subscriber-only newsletters delivered to your inbox daily
with our premium data tools
for the latest news and insights in the world of life sciences, medicine, biotech, and pharma
at exclusive live and virtual events hosted by STAT
with subscriber-only newsletters delivered to your inbox daily
with our premium data tools
By John Wilkerson Nov. 29, 2023
WASHINGTON — The Biden administration is appealing a court ruling against a Trump-era regulation that aimed to protect the way health insurance companies handle some prescription drug costs — a rare moment of harmony between the two administration’s approaches to drug pricing reform.
At issue is a health insurance industry practice of not counting drug company coinsurance assistance toward a patient’s out-of-pocket costs. Health plans use tools, called copay accumulators, to keep tabs on whether patients or drug companies were paying the tab for a certain medicine — and don’t count any drug company assistance toward a patient’s deductible or plan maximum.
advertisement
Insurers say they’re trying to control drug prices. When a drug company pays a patient’s share of a drug’s price, it’s easier to maintain a high price because patients stop caring about it. Medicare bans drug company coinsurance assistance on similar reasoning.
Get unlimited access to award-winning journalism and exclusive events.
Washington Correspondent
John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care.
Congress
drug prices
health insurance
Medicare
pharmaceuticals
policy
STAT+
White House
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let’s stay connected!
To submit a correction request, please visit our Contact Us page.
advertisement
Reporting from the frontiers of health and medicine
Company
Account
More
Become a STAT+ subscriber today!
Become a STAT+ subscriber today!
Unlimited access to essential biotech, medicine, and life sciences journalism
Become a STAT+ subscriber today!
Become a STAT+ subscriber today!
Your go-to source for the latest news and insights on biopharma and the life sciences
Become a STAT+ subscriber today!
Become a STAT+ subscriber today!
Unlimited access to essential biotech, medicine, and life sciences journalism
Become a STAT+ subscriber today!
Become a STAT+ subscriber today!
Your go-to source for the latest news and insights on biopharma and the life sciences